BMJ  2007;335:1119 (1 December), doi:10.1136/bmj.335.7630.1119

News

Shortcuts from other journals

Oral vaccine protects European infants from rotavirus gastroenteritis

The first 150 words of the full text of this article appear below.


Figure Removed (Available Only in the Full Text)
View larger version (25K):



 
 
Rotarix is GlaxoSmithKline's oral vaccine against rotavirus infections. It worked well in Latin America, and the company has now completed a large phase III trial in nearly 4000 infants in Europe. Two doses of the vaccine given with other routine vaccinations reduced rotavirus gastroenteritis by 87.1% (95% CI 79.6 to 92.1) compared with placebo during one rotavirus season and by 78.9% (72.7 to 83.8) over two seasons. The vaccine also prevented 92-100% of hospital admissions for rotavirus infection. These infants had their first dose of vaccine at a mean age of 11.5 weeks and their second at a mean age of 20 weeksGo.

Rotarix is a live attenuated vaccine containing just one strain of rotavirus (G1P(8)). But it also protected infants against other strains and was associated with a 72% reduction in hospital admissions for gastroenteritis of any cause. The groups had an even distribution of serious adverse events, . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ